Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.

Zhang J, Huang Y, Wang C, He Y, Zheng S, Wu K.

Medicine (Baltimore). 2017 Aug;96(33):e7846. doi: 10.1097/MD.0000000000007846.

2.

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.

Yu Z, Guo X, Jiang Y, Teng L, Luo J, Wang P, Liang Y, Zhang H.

Breast Cancer. 2017 Jul 28. doi: 10.1007/s12282-017-0794-8. [Epub ahead of print] Review.

PMID:
28755088
3.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).

Eur J Cancer. 2017 Jul;79:129-138. doi: 10.1016/j.ejca.2017.03.033. Epub 2017 May 8.

PMID:
28494403
4.

Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA.

Curr Med Res Opin. 2017 Aug;33(8):1457-1466. doi: 10.1080/03007995.2017.1325730. Epub 2017 May 16.

PMID:
28463012
5.

Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.

Roberts K, Rickett K, Greer R, Woodward N.

Crit Rev Oncol Hematol. 2017 Mar;111:66-80. doi: 10.1016/j.critrevonc.2017.01.010. Epub 2017 Jan 22. Review.

PMID:
28259297
6.

Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, Azoulay L.

Ann Oncol. 2017 Mar 1;28(3):487-496. doi: 10.1093/annonc/mdw673.

PMID:
27998966
7.

Metabolism and toxicological implications of commonly used chemopreventive drugs against breast cancer/carcinogenesis.

Muhammad A, Ibrahim MA, Erukainure OL, Malami I, Sani H, Mohammed HA.

Curr Drug Metab. 2016 Nov 16. [Epub ahead of print]

PMID:
27848887
8.

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.

Kümler I, Knoop AS, Jessing CA, Ejlertsen B, Nielsen DL.

ESMO Open. 2016 Aug 16;1(4):e000062. eCollection 2016. Review.

9.

Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.

Niraula S, Ocana A.

Cancer Treat Rev. 2016 Nov;50:168-174. doi: 10.1016/j.ctrv.2016.09.011. Epub 2016 Sep 20. Review.

PMID:
27693931
10.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ.

J Clin Oncol. 2016 Sep 1;34(25):3069-103. doi: 10.1200/JCO.2016.67.1487. Epub 2016 May 23.

PMID:
27217461
11.

Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer.

Wang W, Liu C, Zhou W, Xia T, Xie H, Wang S.

Sci Rep. 2016 May 13;6:25615. doi: 10.1038/srep25615.

12.

Treatment Modification in Young Breast Cancer Patients.

Scharl A, Salterberg A, Untch M, Liedtke C, Stickeler E, Papathemelis T.

Oncol Res Treat. 2016;39(3):122-8. doi: 10.1159/000444355. Epub 2016 Feb 24. Review.

13.
14.

Palbociclib for the treatment of postmenopausal breast cancer - an update.

Steger GG, Gnant M, Bartsch R.

Expert Opin Pharmacother. 2016;17(2):255-63. doi: 10.1517/14656566.2016.1133590. Epub 2016 Jan 14. Review.

PMID:
26679057
15.

Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.

Mocellin S, Pilati P, Briarava M, Nitti D.

J Natl Cancer Inst. 2015 Nov 18;108(2). pii: djv318. doi: 10.1093/jnci/djv318. Print 2016 Feb.

PMID:
26582062
16.

Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.

Zhao X, Liu L, Li K, Li W, Zhao L, Zou H.

Onco Targets Ther. 2015 Sep 29;8:2721-30. doi: 10.2147/OTT.S88179. eCollection 2015.

17.

Anti-Hormonal Therapies for Premenopausal Patients--What did we Learn from the TEXT/SOFT Trials?

Valsecchi ME, Recondo G, de la Vega M, Greco M, Recondo G, Díaz Cantón E.

Rev Recent Clin Trials. 2015;10(2):90-100. Review.

PMID:
26216437
18.

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R.

Breast Cancer Res Treat. 2015 Jul;152(1):95-117. doi: 10.1007/s10549-015-3453-9. Epub 2015 Jun 5.

PMID:
26044370
19.

Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.

Grassadonia A, Caporale M, Tinari N, Zilli M, DeTursi M, Gamucci T, Vici P, Natoli C.

J Cancer. 2015 May 12;6(6):575-82. doi: 10.7150/jca.11566. eCollection 2015. Review.

20.

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members.

Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.

Supplemental Content

Loading ...
Support Center